Summary
A method of testing for neutralisation of the cancer coagulative factor is described.
Of a wide range of substances tested, protamine sulphate, placentalα 1 globulin and placental albumin were found to possess activity worthy of clinical investigation in the treatment of cancer.
Plasmin is also highly active in counteracting the clotting effect of the cancer coagulative factor. Its probable mode of action is unspecific proteolysis, comparable with its effect on many of the recognised factors concerned in coagulation of the blood.
Similar content being viewed by others
References
O’Meara, R. A. Q. (1958).Irish J. Med. Sci., vi, 394, 474.
O’Meara, R. A. Q. (1960).Arch. de Vecchi, 31, 365.
O’Meara, R. A. Q., and Thornes, R. D. (1961).Irish J. Med. Sci., vi, 423, 106.
Sherry, S., Fletcher, A. D., and Alkjaersig, N. (1959).Physiol. Rev., 39, 343.
Thornes, R. D., and Martin, W. T. (1961).In preparation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thornes, R.D., O’Meara, R.A.Q. A method of detecting and estimating inhibitors of the cancer coagulative factor. Ir J Med Sci 36, 361–365 (1961). https://doi.org/10.1007/BF02953365
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02953365